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ABSTRACT
Despite the development of specific therapies for pulmonary
arterial hypertension (PAH) some patients fail to respond to
such treatment. One of the potential reasons for the unre-
sponsiveness to targeted therapies may be the presence of
fibrous occlusion of small pulmonary veins that accompanies
pre-capillary arteriopathy. This type of pathologic change is
called pulmonary veno-occlusive disease (PVOD).
Underdiagnosed PVOD occurs probably in 5-10% of idiopath-
ic pulmonary hypertension (IPAH) and in a substantial pro-
portion of PAH related to connective tissue diseases (mainly in
scleroderma). A definite diagnosis of PVOD requires histologi-
cal examination of lung sample, but surgical lung biopsy in pul-
monary hypertension is combined with high risk of bleeding.
Thus major interest is focused on a non-invasive diagnostic
approach enabling early recognition of PVOD and referral for
lung transplantation. The present review is focused on the radio-
logical features suggestive of PVOD-like vasculopathy in PAH. 
Keywords: CT scan, idiopathic pulmonary hypertension,
mosaic lung attenuation, pulmonary veno-occlusive disease. 
RIASSUNTO 
Nonostante lo sviluppo di trattamenti specifici per l’iperten-
sione arteriosa polmonare (PAH) alcuni pazienti non rispon-
dono alla terapia. 
Una delle possibili ragioni può essere la presenza di un’occlu-
sione fibrotica delle piccole vene polmonari in associazione
con una arteriopatia pre-capillare. Questo tipo di alterazio-
ne è denominata malattia polmonare veno-occlusiva
(PVOD). Probabilmente una PVOD non diagnosticata sot-
tende a circa il 5-10% delle forme di ipertensione polmona-
re idiopatica (IPAH) ed a una quota rilevante delle forme di
PAH secondarie a collagenopatie (soprattutto la scleroder-
mia). Per una diagnosi di certezza di PVOD è necessario l’e-
same istologico di un campione di tessuto polmonare, ma
una biopsia polmonare chirurgica nell’ipertensione polmo-
nare è ad alto rischio di sanguinamento. Vi è quindi un gran-
de interesse per individuare un approccio diagnostico non
invasivo che permetta un riconoscimento precoce della
PVOD e l’avvio al trapianto polmonare. Questa rassegna è
incentrata sugli aspetti radiologici suggestivi di una vasco-
lopatia tipo PVOD nella PAH.
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6 Parole chiave: Ipertensione polmonare idiopatica, malattia
polmonare veno-occlusiva, pattern di attenuazione a mosai-
co, TAC torace.  
Definition and classification of pulmonary hyper-
tension
Hemodynamic diagnosis of pulmonary hyperten-
sion (PH) requires the presence of mean pulmonary
artery pressure (mPAP) of 25 mm Hg or higher [1-
3]. PH is further characterized as pre-capillary (with
pulmonary capillary wedge pressure [PCWP] ≤ 15
mm Hg) or post-capillary or venous (with PCWP >
15 mm Hg) [1-3]. PH has been divided into 5
groups depending on the underlying pathomech-
anism. The latest update of this classification (Table
I) was in 2008 [1-3]. 
The common feature for group 1, called pulmonary
arterial hypertension (PAH), is pre-capillary pul-
monary arteriopathy. This group includes: idiopath-
ic PAH, heritable PAH, and PAH associated with:
connective tissue diseases (CTD), congenital heart
diseases (CHD), systemic-to-pulmonary shunts, por-
tal hypertension, HIV, use of drugs or anorexigens
and many other conditions listed in Table I. 
The two entities: pulmonary veno-occlusive disease
(PVOD) and pulmonary capillary hemangiomatosis
(PCH) were removed from group 1 to a separate
group 1’, due to the different pathomechanism of
pulmonary hypertension (pathologic changes local-
ized in capillaries and in small venules, causing
capillary hypertension and secondary arterial
hypertension).
Group 2 is composed of PH as a consequence of
left heart pathology.
Group 3 encompasses PH related to pulmonary dis-
ease leading to capillary destruction and/or hypoxic
pulmonary vasoconstriction.
Group 4 consists of PH due to chronic thromboem-
bolic pulmonary disease (CTEPH).
Group 5 is composed of PH with unclear or multi-
factorial mechanisms. 
Differential diagnosis of PH
The routine diagnostic procedures involved in the
differential diagnosis of PH consist of physical
examination, blood and serologic tests, chest radio -
gram, echocardiographic study, chest computerized
tomography (CT) scan, ventilation-perfusion scintig-
raphy and pulmonary function tests (PFT) [4,5].
Right heart catheterization is not only obligatory for
confirmation of PH, but it is also a very important
tool in the differential diagnosis of other forms of
PH [4,5]. 
Thus PH related to parenchymal lung diseases and
chronic obstructive pulmonary disease (COPD) is
diagnosed when significant PFT abnormalities +/-
pathologic parenchymal changes in lung CT scan
are found. In the case of PH in the course of
obstructive sleep apnea, pathologic polysomno -
graphy is diagnostic.
PH related to left heart diseases (venous, post-capil-
lary PH) is diagnosed in the case of left heart myocar-
dial or valvular disease with increased PCWP. 
CTEPH is diagnosed in those patients with PH who
present segmental hypoperfusion areas on lung per-
fusion scan (scintigraphy with high probability of
pulmonary embolism). The majority of these
patients have had an episode of symptomatic
venous thromboembolic disease in their medical
history, and in some of them intravascular filling
defects can be demonstrated on chest CT angio -
graphy or arteriography [2]. 
PAH is diagnosed after the exclusion of the above-
mentioned, most frequent causes of PH. It is the
most extensively investigated group due to the pos-
sibility of specific therapeutic approaches: prosta -
cyclin derivatives, endothelin receptor antagonists
and phosphodiesterase-5 inhibitors [5-8].
Prolonged specific treatment of PAH is combined
with a significant improvement of functional class,
increase of exercise tolerance measured by the 6-
minute walking test (6MWT), a decrease in serum
biomarkers of myocardial injury and decompensa-
tion (troponin, BNP, NT-proBNP) and an improve-
ment of pulmonary hemodynamics [5,9-11]. The
results of a large meta-analysis involving 3,140
patients from 21 studies, presented recently by
Galié et al. [12], indicate also a positive prognostic
influence of specific treatment in PAH (43% reduc-
tion in mortality over 14.3 weeks). 
Reasons for the poor response to specific treat-
ment in PAH 
Despite progress in specific treatment of PAH, there
are some patients in whom the treatment is ineffec-
tive or even combined with a worsening of clinical
symptoms.
This happens most frequently in PVOD/PCH, where
the presence of capillary and post-capillary occlu-
sion causes an increase of trans-capillary pressure
with signs and symptoms of pulmonary congestion
[13]. Underdiagnosed PVOD occurs probably in 5-
10% of IPAH [13]. The clinical presentation of such
cases may be indistinguishable from IPAH, except-
ing for a rapid development of pulmonary edema
after administration of vasodilators. Harch et al.
[13] examined lung specimens available from
autopsy or explantation in 14 patients with clinical-
ly diagnosed PAH who had failed to respond to
medical therapy and found PVOD in 86% of them
and “arterial-only” PAH in the remaining 14%.
Montani et al. [14] described the development of
pulmonary edema (mostly with continuous intra-
venous epoprostenol, but also with oral bosentan
and calcium channel blockers) in 7/16 patients with
pathologically proved PVOD (43.8%) at a median
of 9 days after treatment initiation. 
The definite diagnosis of PVOD/PCH requires a
pathologic examination of lung tissue. Lung biopsy
is contraindicated in the majority of patients with
PH, due to the possibility of life-threatening bleed-
ing [15,16]. Thus pathologic material is usually
obtained from explanted lung or - unfortunately -
during autopsy. 
In PVOD fibrous venules remodeling with second-
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sis, interstitial edema and lymphatic dilatation is
found [17,18]. Pulmonary and mediastinal lymph
nodes enlargement due to venous congestion and
veno-lymphatic shunts has been described by
Montpréville et al. [19].
In PCH, capillary proliferation develops, either as
the isolated pathology or, more frequently, as a
reaction to increased venous pressure due to
venous occlusion. Thus most pathologists use the
name PVOD/PCH for such pathology [17,18].
Despite the occurrence of secondary pre-capillary
arteriopathy in some PVOD/PCH cases, no com-
plex lesions in pulmonary arteries are observed
[17,18]. 
Poor results of specific treatment may be also
observed in PAH related to CTD [20-22]. Despite
some recently reported therapeutic achievements in
PAH-CTD [23-25], the results are worse than in
IPAH. Dorfmuller et al. [26] described recently
fibrous remodeling of the pulmonary venous system
in PAH-CTD. This phenomenon may explain why
these patients are less prone to respond to specific
PAH treatment compared with IPAH. The authors
suggest a clinically relevant hemodynamic effect of
post-capillary occlusion in a setting of PAH-CTD,
with PVOD-like pathology. PVOD-like pathology
was described in PAH-CTD also by Overbeck et al.
[27] and in the course of fatal granulomatous angi-
itis by Dwyer et al. [28]. 
The search for clinical markers of PVOD/PCH drew
attention to the presence of lung pathology seen
occasionally on CT scans in PAH.
Value of lung CT scan in PAH
In the majority of IPAH patients the only radiologi-
cal abnormality seen on CT scans are the signs of
pulmonary hypertension such as dilatation of pul-
monary artery, pulmonary artery/aorta diameter > 1
and right ventricular enlargement [29].
Nevertheless some investigators have noted the
TABLE I: UPDATED CLINICAL CLASSIFICATION OF PULMONARY HYPERTENSION    




1.2.2 ALK1, endoglin (with or without hereditary hemorrhagic teleangiectasia)
1.2.3 Unknown
1.3 Drugs and toxins induced
1.4 Associated with (APAH):
1.4.1 Connective tissue diseases
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.4.6 Chronic haemolytic anemia
1.5 Persistent pulmonary hypertension of the newborn 
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis




3. Pulmonary hypertension due to lung diseases and/or hypoxemia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension
5. Pulmonary hypertension with unclear and/or multifactorial mechanisms
5.1 Hematological disorders: myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders































6 presence of mosaic attenuation on HRCT scans in
IPAH patients. 
Stern et al. [30] made an effort to categorize the dis-
eases leading to mosaic pattern of lung attenuation.
Three categories of lung disease are known to cause
a mosaic pattern of lung attenuation on CT scan:
small airways diseases, pulmonary vascular dis-
eases and infiltrative lung diseases. 
The mosaic pattern of lung attenuation caused by
small airways diseases is a result of air trapping. This
condition is recognized on CT scans obtained at full
expiration. The mosaic pattern of lung attenuation
caused by primary vascular disease is caused by
regions of hyperemic lung (with higher attenuation)
adjacent to oligemic regions of the lung (with lower
attenuation). Mosaic attenuation due to vascular
disease and due to small airways disease may pro-
duce a similar CT picture performed at inspiration –
with decrease of size and number of vessels in
lucent parts of the lung compared with the regions
with higher attenuation. Nevertheless no air trap-
ping is seen on expiratory CT in the case of vascular
disease. 
The third cause of mosaic lung attenuation is an
infiltrative lung disease, with areas of ground-glass
attenuation due to interstitial or air space infiltrates,
or both. In this condition no air trapping is seen on
expiratory CT but the number and size of vessels in
the areas of ground glass attenuation is similar to
the areas of normal lung parenchyma. 
The heterogeneity of perfusion in lung vascular
pathology is most prominent in CTEPH due to the
fact that the caliber of occluded vessels is greater
than in PAH. So the areas of hypo- and hyper-perfu-
sion are large enough to be seen on CT scans. This
type of perfusion heterogeneity is called mosaic
perfusion (Figure 1).
The heterogeneity of perfusion in PAH is less promi-
nent than in CTEPH, due to the smaller caliber of
occluded vessels and more dispersed nature of the
disease. Thus in the majority of PAH patients hetero-
geneity of lung perfusion is not seen. Nevertheless
in some IPAH patients inhomogeneity of lung
parenchyma is recognized but the mechanism
involved in this pathology and the clinical signifi-
cance of such finding is not clear. 
Resten et al. [31] analyzed HRCT in 12 IPAH
patients with epoprostenol therapy failure (group 1)
and compared them to 61 patients who improved
during such therapy (group 2). Frequency of
ground-glass opacities in groups 1 and 2 was,
respectively, 83% and 38%. The authors divided
ground-glass opacities into two categories: class I –
poorly defined nodular opacities ranging in diame-
ter from a few millimeters to 1 centimeter with cen-
trilobular distribution, and class II - pan-lobular dis-
tribution of geographic regions of lung attenuation
with relatively well defined borders. Class I opaci-
ties were found more frequently in group 1 than in
group 2 (61% and 21%, respectively). The frequency
of class II opacities was similar in both groups (25%
and 16% respectively). Thus only the presence of
class I opacities correlated with the failure of
epoprostenol therapy. The other parameters corre-
lated with epoprostenol failure were: thickened
interlobular septa, mediastinal lymphadenopathy
and the presence of pericardial effusion. The results
of post-mortem examination were available in 6
patients from group 1 and revealed the presence of
PVOD or PCH in all of them. The authors conclud-
ed that the presence of poorly defined centrilobular
opacities in combination with thickened septal
lines, pleural or pericardial effusion and/or
adenopathy in the patients with IPAH should raise a
suspicion of PVOD or PCH.
The occurrence of centrilobular nodules in 25% of
PAH patients was also described by Nolan et al.
[32], who found the presence of cholesterol granu-
lomas in them on pathologic examination. The
mechanism of development of such granulomas
could be related, according to the authors, to the
degradation of excess of surfactant or to recurrent
pulmonary hemorrhage. The nodules described by
Nolan et al. [32] in PAH were an isolated finding,
with no septal lines or lymphadenopathy. 
In our own research [33], the retrospective analysis
of HRCT scans revealed the presence of various
forms of ground-glass opacities in 20 out of 48
(41%) IPAH patients (Figure 2). According to their
morphology they were divided into two groups:
poorly defined centrilobular nodules (correspond-
ing to the class I pathology of Resten et al.) – 17%
(Figure 2c) and focal ground-glass opacities with
perihilar, peripheral or global localization (corre-
sponding to the class II pathology of Resten et al.) –
23% (Figure 2a,b). In the group of patients with
centrilobular nodules, significantly higher mean
right atrial pressure (12.2 ± 4.9 mm Hg versus 7.6 ±
5.3 mm Hg) and lower mean stroke volume (41 ±
8.5 ml versus 58 ± 18 ml) were found compared to
the remaining IPAH patients. The presence of nod-
ules was combined with poor prognosis (5-fold
FIGURE 1: CHEST HRCT IMAGE FROM PATIENT WITH
CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
– MOSAIC PERFUSION
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higher risk of death compared to the remaining
IPAH patients). Centrilobular nodules were found to
be a strong independent poor prognostic indicator
in our group of IPAH patients. It is not clear whether
this population represented an underdiagnosed
PVOD-like pathology or a distinct radiological
IPAH pattern combined with poor prognosis. 
No other features suggestive of PVOD were found
in our material.
Radiological features of PVOD/PCH
PVOD/PCH with the pathological changes seen in
small venules and capillaries produces the radio-
logical signs of pulmonary congestion and impaired
lymphatic drainage. The typical radiological
changes described on CT scans in PVOD represent
the combination of septal lines, lymphadenopathy
and pleural effusion. Many authors have also noted
the presence of poorly defined centrilobular nodu-
lar opacities in PVOD. 
Resten et al. [34] analyzed radiological features of
pathologically confirmed PVOD in 15 patients and
compared them with radiological features of 15
PAH patients. He found the presence of ground-
glass opacities in 87% of PVOD and in 33% of PAH
(p = 0.003), septal lines in 93% of PVOD and 13%
of PAH (p < 0.0001) and lymph nodes enlargement
in 80% of PVOD and 0% of PAH (p < 0.0001). The
presence of pleural effusion, noted in 23% of
PVOD and 13% of PAH, was not helpful in the dif-
ferential diagnosis. The authors concluded that
pleural effusion is a less specific sign of PVOD and
should be regarded as characteristic only in the
presence of other radiological PVOD features. This
observation was confirmed by data reported by
Tang et al. [35], who demonstrated pleural effusion
in 25% of IPAH, mostly due to right heart failure.
The patients with pleural effusion had significantly
higher mean right atrial pressure (mRAP) than the
remaining patients (16.0 ± 6.8 mm Hg and 8.8 ±
5.5 mm Hg respectively). The majority of effusions
were small and right sided. 
The type of ground-glass opacities found by Resten
et al. [34] was either centrilobular or pan-lobular.
Centrilobular nodules were more characteristic of
PVOD; nevertheless they appeared occasionally
also in PAH. 
It is not clear whether centrilobular nodules seen in
PVOD represent a venopathy or alveolar consolida-
tions due to lung congestion. Cassart et al. [36]
described a complete resolution of ground-glass
opacities in native lung 84 days after single lung
transplantation in PVOD. This finding might support
the theory of centrilobular nodules as a sign of pul-
monary congestion in the presence of impaired out-
flow on the level of small pulmonary veins. 
Dufour et al. [37] described small, centrilobular,
poorly circumscribed nodular opacities in combi-
nation with thickening of interlobular septa in 2
patients with PCH and 2 patients with PVOD (biop-
sy proven). All these patients developed fatal pul-
monary edema after treatment with intravenous
epoprostenol. 
The combination of centrilobular ground-glass
opacities, septal lines and lymph nodes enlarge-
ment on lung CT scan had, according to Montani et
al. [38], a 75% sensitivity and 85% specificity for
detection of PVOD. Nevertheless the absence of
such changes or the presence of only one radiolog-
ical abnormality could not rule out PVOD.
El-Gabaly et al. [39] reported a case of PCH con-
firmed by open lung biopsy presenting on HRCT
scans with numerous ill-defined centrilobular
FIGURE 2: CHEST HRCT IMAGES FROM PATIENTS WITH IPAH
(A-C). PATCHY (A) AND PERIHILAR (B) GROUND-GLASS
OPACIFICATIONS; CENTRILOBULAR NODULES (C)



































micronodular densities affecting both lungs, with
no other radiological abnormalities. Isolated cen-
trilobular ground-glass opacities were described
recently by Iwaki et al. [40] in a 52-year-old female
with biopsy-proven PVOD. 
Differential diagnosis of PVOD/PCH and IPAH
Montani et al. [38] summarized clinical PVOD fea-
tures that help to differentiate it from IPAH (Table II).
They are: higher male/female ratio, higher tobacco
exposure, lower arterial oxygen at rest, lower diffus-
ing capacity for carbon monoxide and lower oxy-
gen saturation nadir during 6MWT. 
The other important feature of PVOD is the pres-
ence of occult alveolar hemorrhage. This observa-
tion was made by Rabiller et al. [41], who found in
bronchoalveolar lavage a higher percentage of
hemosiderin laden macrophages in PVOD com-
pared to IPAH. 
The reasons for a worse hypoxemia in PVOD than
expected from PAP levels are: pulmonary edema,
alveolar hemorrhage and overall more extensive
obliteration of the pulmonary vascular bed.
Montani et al. [38] found no significant differences
in hemodynamic parameters between PVOD and
IPAH. PCWP is not greater in PVOD compared to
IPAH, as it reflects the pressure in the pulmonary
veins with a caliber similar to the pulmonary artery
branch where the catheter is inserted and the occlu-
sion maneuver performed, whilst the caliber of
small veins and venules affected by PVOD is small-
er. 
Holcomb et al. [42] presented data concerning
poor prognosis in PVOD: the 1-year mortality rate
may be as high as 72%. Montani et al. [38] found
the mean time from diagnosis to death or lung
transplant in PVOD to be 11.8 ± 16 months, which
was significantly worse than in IPAH (42.3 ± 29.9
months). The worse outcome of PVOD patients is
probably related to the development of pulmonary
edema either as part of the natural course of the dis-
ease or as precipitated by specific pulmonary
vasodilator therapies. Due to the worse prognosis in
PVOD patients and no evidence of effective phar-
macotherapy, it is important to consider lung trans-
plantation early in the course of the disease.
In summary, PVOD/PCH is a disease difficult to
diagnose, in some cases presenting with a wide
spectrum of radiologic abnormalities, but in many
others indistinguishable from IPAH until the devel-
opment of signs of pulmonary congestion in the
course of treatment with vasodilators. The presence
of ill-defined centrilobular nodules on lung HRCT
scan in IPAH especially in combination with thick-
TABLE II: DIFFERENTIAL DIAGNOSIS OF IDIOPATHIC PAH AND IDIOPATHIC PVOD     
IPAH PVOD
Genetic mutations BMPR2 mutations 10-40% Cases of BMPR2 mutation
Epidemiology
Sex F:M = 2 F:M = 1
Tobacco exposure Unrelated More frequent than in IPAH
Chemotherapy Case reports Case reports
Clinical examination
Auscultatory crackles No Possible
Clubbing Possible Possible
Hemoptysis Possible Possible
Pulmonary function tests Normal (possible mild restrictive) Normal (possible mild restrictive)
DLCO and DLCO/VA Often reduced Reduced, lower than IPAH
PaO2 at rest Often reduced Reduced, lower than IPAH




BAL Normal Possible occult alveolar hemorrhage
Acute NO testing Positive: predictive of Not a predictor of CCB response
CCB response and better (risk of pulmonary edema after initiation of CCB)
prognosis
Response to PAH therapy Improved hemodynamics, PVOD may deteriorate with a risk 
functional status and outcome of pulmonary edema
Definition of abbreviations: BAL, bronchoalveolar lavage; CCB, calcium channel blockers; DLCO, diffusing lung capacity for carbon monoxide;
HRCT, high resolution computerized tomography; IPAH, idiopathic pulmonary arterial hypertension; NO, nitric oxide; PaO2, partial pressure of
arterial oxygen; PAH, pulmonary arterial hypertension; PVOD, pulmonary veno-occlusive disease; VA, alveolar ventilation.
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ened septal lines and/or lymphadenopathy should
draw attention to the possibility of a PVOD-like
pathology. Targeted therapies should be applied
with caution in such patients. 
Lack of effect of targeted therapy should be a reason
for early referral for lung transplantation. 
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